)
Visual
earnings real time
Balaxi Pharmaceuticals
Balaxi Pharmaceuticals (BALAXI) investor relations material
Balaxi Pharmaceuticals Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 25/26 earnings summary28 Jan, 2026
Executive summary
Achieved strong sequential revenue recovery in Q3 FY26, up 29% QoQ to ₹72.54 crore, but down 1% YoY due to Angola market challenges and extended working capital cycles in institutional and hospital segments.
Gross profit margin moderated to above 42% (vs. 48% YoY), with bottom line declining to ₹0.31 crore from ₹5.36 crore YoY, mainly due to elevated operating costs from strategic market shifts.
Significant operational progress on the new pharmaceutical formulation facility in Hyderabad/Jadcherla, with audit readiness and successful validation completed.
Standalone and consolidated unaudited financial results for Q3 and nine months ended 31.12.2025 were approved and released, with statutory auditor review completed.
LATAM region emerged as a key growth driver, supported by a robust order pipeline and 13 new product registrations, totaling 948 across geographies.
Financial highlights
Q3 FY26 consolidated revenue at ₹72.54 crore, up 29% QoQ but down 1% YoY; gross profit at ₹30.81 crore, up 4.6% YoY.
Gross margin improved by 229 bps YoY to 42.5%; EBITDA at ₹3.19 crore, down 59.8% YoY; EBITDA margin at 4.4%, down 642 bps.
PAT at ₹0.31 crore, down 94.3% YoY; PAT margin at 0.4% vs. 7.3% YoY; EPS at ₹0.06, down 93.8% YoY.
FY25 revenue grew 21.2% YoY to ₹292.56 crore; gross profit up 12.6% to ₹126.86 crore; gross margin at 43.4% (down 331 bps YoY).
FY25 EBITDA at ₹33.50 crore (down 24% YoY); PAT at ₹25.07 crore vs. loss of ₹2.39 crore in FY24, which included a one-time FX loss in Angola.
Outlook and guidance
Management anticipates margin recovery and sustainable long-term growth, driven by improved regional traction, operating leverage, and the new Hyderabad facility.
The Jadcherla formulation facility is fully prepared for regulatory inspection, indicating potential for future revenue growth from new manufacturing capabilities.
Robust order pipeline in LATAM expected to support top-line growth in coming quarters.
Jadcherla plant CDSCO inspection timeline
What caused the Q3 consolidated profit decline?
Rationale for unreviewed subsidiary financials
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- DEVYANI
Revenue increased but net losses persisted; major acquisitions and amalgamation approved. - DNB
Q4 2025 saw strong growth and high returns, but annual profit fell due to higher costs and impairments. - DNBQ4 2025 profit NOK 11.6bn, 16.6% ROE, NOK 18 dividend, and strong CET1 at 17.9%.
- PARADEEP
Revenue and profit surged on higher volumes, MCFL merger, and expansion, with regulatory changes noted. - 2454
Q4 2025 saw strong revenue growth but lower net income and margins amid rising costs. - QBY
Profitability focus drives AI investment, international growth, and share buyback plans. - WRT1V
All-time high profit and cash flow, with robust Marine and Energy growth and key divestments. - NOBA
Record profit growth, robust capital, and SME expansion via acquisition in 2025. - 8354
Profit and net income rose over 15% YoY, with higher guidance and improved asset quality. - 4208
Operating profit surged 52% despite lower sales, driven by restructuring and acquisitions.
Next Balaxi Pharmaceuticals earnings date
Q4 25/2628 May, 2026
Balaxi Pharmaceuticals
Next Balaxi Pharmaceuticals earnings date
Q4 25/2628 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Balaxi Pharmaceuticals Limited is a pharmaceutical company engaged in the manufacturing, marketing, and distribution of branded generic formulations. The company offers a wide range of dosage forms including tablets, capsules, syrups, and injectables across various therapeutic segments such as anti-infectives, gastroenterology, and pain management. The company is headquartered in Hyderabad, India, and its shares are listed on the BSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage